Barbara Spitzer

List of Publications by Year
in descending order

34 papers	2,272 citations	567281 15 h-index	501196 28 g-index
34 all docs	34 docs citations	34 times ranked	5015 citing authors

#	Article	IF	Citations
1	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	21.4	367
2	Loss of BAP1 function leads to EZH2-dependent transformation. Nature Medicine, 2015, 21, 1344-1349.	30.7	297
3	Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood, 2014, 124, 1790-1798.	1.4	204
4	Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature, 2016, 531, 471-475.	27.8	202
5	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature Medicine, 2016, 22, 1488-1495.	30.7	195
6	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood, 2019, 134, 2361-2368.	1.4	190
7	Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. Journal of Clinical Investigation, 2020, 130, 733-747.	8.2	161
8	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. Journal of Experimental Medicine, 2015, 212, 1819-1832.	8.5	137
9	CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell, 2015, 28, 15-28.	16.8	124
10	Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget, 2016, 7, 83208-83222.	1.8	73
11	JAK2/IDH-mutantâ€“driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. Journal of Clinical Investigation, 2018, 128, 789-804.	8.2	66
12	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. Nature Communications, 2021, 12, 338.	12.8	64
13	MEF2C Phosphorylation Is Required forÂChemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discovery, 2018, 8, 478-497.	9.4	59
14	Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation. Cytotherapy, 2020, 22, 503-510.	0.7	27
15	Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia. Frontiers in Oncology, 2015, 5, 16.	2.8	24
16	Antithymocyte globulin exposure in CD34+ T-cellâ€“depleted allogeneic hematopoietic cell transplantation. Blood Advances, 2022, 6, 1054-1063.	5.2	12
17	Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplantation, 2020, 55, 2160-2169.	2.4	11
18	Posttransplant Lymphoproliferative Disorder Complicating Hematopoietic Stem Cell Transplantation in a Patient With Dyskeratosis Congenita. International Journal of Surgical Pathology, 2013, 21, 520-525.	0.8	9

#	Article	IF	Citations
19	A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2017, 23, 2088-2095.	2.0	9
20	Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. Biology of Blood and Marrow Transplantation, 2016, 22, 1449-1454.	2.0	8
21	<i>ETV6-FLT3â€“</i>positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML. Blood Advances, 2021, 5, 1899-1902.	5.2	8
22	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature Medicine, 2016, 22, 578-579.	30.7	7
23	Late complications of mixed chimerism following allogeneic bone marrow transplantation for thalassemia major. Pediatric Blood and Cancer, 2015, 62, 1303-1304.	1.5	5
24	Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. Clinical Cancer Research, 2022, 28, 1614-1627.	7.0	4
25	Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access. Blood, 2020, 136, 23-24.	1.4	3
26	AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival. Blood, 2018, 132, 1471-1471.	1.4	2
27	De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes. Blood, 2019, 134, 2708-2708.	1.4	2
28	De Novo Skin Xerosis in Cord Blood Transplantation is Associated with Distinct Histopathology and Treatment Response: First Literature Report of Cord Dermatosis. Biology of Blood and Marrow Transplantation, 2018, 24, S193-S194.	2.0	1
29	Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis. Blood, 2015, 126, 435-435.	1.4	1
30	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. Journal of Cell Biology, 2015, 211, 2111OIA226.	5.2	0
31	Early Detection and Molecular Characterization of Therapy-Related Leukemia in Children Reveals Patterns of Disease Transformation and Guides Future Surveillance Protocols. Blood, 2018, 132, 291-291.	1.4	0
32	Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL. Blood, 2019, 134, 4582-4582.	1.4	0
33	Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis. Blood, 2020, 136, 29-30.	1.4	0
34	Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults. Blood, 2020, 136, 30-31.	1.4	0